{
    "clinical_study": {
        "@rank": "124439", 
        "arm_group": [
            {
                "arm_group_label": "Rotigotine group", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo group", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo matched to rotigotine will be administered in the same way as within the Rotigotine group."
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this trial is to investigate the PK (Pharmacokinetic) of repeated-dose\n      applications of the Rotigotine transdermal patch in healthy young male and female Korean\n      subjects to be submitted to MFDS for new drug application approval."
        }, 
        "brief_title": "Trial to Evaluate the Pharmacokinetics, Safety, and Tolerability of Rotigotine in Healthy Korean Subjects", 
        "completion_date": {
            "#text": "February 2007", 
            "@type": "Actual"
        }, 
        "condition": "Parkinson's Disease", 
        "condition_browse": {
            "mesh_term": "Parkinson Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject is male or female and aged between 19 and 45 years of age (inclusive)\n\n          -  Subject is healthy (no clinically relevant findings in any of the investigations of\n             the pre-examination) as judged by the investigator\n\n          -  Subject is of normal body weight as determined by a Body Mass Index (BMI) between 18\n             and 28 kg / m\u00b2\n\n          -  Subject is Korean (both parents are pure Korean)\n\n        Exclusion Criteria:\n\n          -  Subject has had a history of drug or alcohol abuse within the last 2 years\n\n          -  Subject has had a history of transient ischemic attack or stroke within the last 12\n             months\n\n          -  Subject has a history or current condition of Epilepsy and / or seizures\n\n          -  Subject has a history of significant skin hypersensitivity to adhesives or other\n             transdermal products or recently unsolved Contact Dermatitis\n\n          -  Subject has a history or present condition of an Atopic or Eczematous Dermatitis,\n             Psoriasis, and / or an active skin disease\n\n          -  Female subject is pregnant or lactating\n\n          -  Subject has any medical or psychiatric condition that, in the opinion of the\n             investigator, could jeopardize or would compromise the subject's ability to\n             participate in this trial\n\n          -  Subject has a QTcB (according to Bazett\u00b4s formula) interval of \u2265 450 ms for female or\n             \u2265 430 ms for male or any other clinically relevant Electrocardiogram (ECG) finding\n\n          -  Subject has any clinically relevant abnormality in the physical examination, or any\n             clinically relevant deviation from the normal range in the clinical chemistry,\n             hematology, or urinalysis\n\n          -  Subject has a relevant hepatic dysfunction (total Bilirubin > 2 mg /dL or Alanine\n             Aminotransferase [ALT] or Aspartate Aminotransferase [AST] greater than 2 times the\n             upper limit of the normal reference range)\n\n          -  Subject has a positive test for Human Immunodeficiency Virus antibodies (HIV)-1/2Ab,\n             Hepatitis B surface Antigen (HBsAg) or Hepatitis C Virus Antibody (HCV-Ab)\n\n          -  Subject has a positive test for alcohol or drugs\n\n          -  Subject consumes more than 150 g of alcohol / week\n\n          -  Subject has made a blood donation or had a comparable blood loss (> 400 ml) within\n             the last 3 months\n\n          -  Subject smokes more than 5 cigarettes per day or has done so within previous 6 months\n\n          -  Subject has a clinically relevant allergy\n\n          -  Subject is taking any medication (excluding oral hormonal contraceptive) currently or\n             within 2 weeks prior to the first day of dosing (with the exception of Acetaminophen\n             [up to 1000 mg per day per os] which may have been taken up to 48 hours prior to\n             commencement of dosing)\n\n          -  Female subject is currently taking an oral hormonal contraceptive but less than 2\n             months\n\n          -  Subject has a symptomatic orthostatic hypotension with a decrease of Blood Pressure\n             (BP) from supine to standing position of \u2265 20 mmHg in systolic BP or of \u2265 10 mmHg in\n             diastolic BP after 1 and / or 3 minutes\n\n          -  Subject has a pulse rate at rest less than 45 beats per minute or more than 100 beats\n             per minute (measured in supine position)\n\n          -  Subject has a systolic Blood Pressure (BP) lower than 100 mmHg or higher than 150\n             mmHg or diastolic BP higher than 95 mmHg (measured in supine position)\n\n          -  Subject has a current or a history of clinically relevant motor disturbance,\n             impairment of memory, sleep disturbance or neurodegenerative disease (e.g. ,\n             Alzheimer Dementia, Diffuse, Lewy Body Dementia, Amyotrophic Lateral Sclerosis [ALS],\n             Multiple Sclerosis)\n\n          -  Subject has taken herbal medicine therapy within the last 2 weeks\n\n          -  Subject consumes more than 3 cups (more than 450 ml) of caffeinated beverages per day\n             within the last 2 weeks"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01964573", 
            "org_study_id": "SP885"
        }, 
        "intervention": [
            {
                "arm_group_label": "Rotigotine group", 
                "description": "Day 1-3: 2 mg patch once daily\nDay 4-6: 4 mg patch once daily", 
                "intervention_name": "Rotigotine", 
                "intervention_type": "Drug", 
                "other_name": "Neupro"
            }, 
            {
                "arm_group_label": "Placebo group", 
                "description": "Placebo patches matching with Rotigotine 2 mg patches and 4 mg patches.\nFrequency:\nDay 1-3: 2 mg patch once daily\nDay 4-6: 4 mg patch once daily", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "N 0437"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Parkinson's Disease", 
            "Rotigotine", 
            "Pharmacokinetics", 
            "Healthy subjects"
        ], 
        "lastchanged_date": "October 16, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Single-site, Randomized, Double-blind, Placebo-controlled, Repeated-dose Trial to Evaluate the Pharmacokinetics, Safety, and Tolerability of Rotigotine in 2 Different Dosages (2 mg / 24 Hours [10 cm2], 4 mg / 24 Hours [20 cm2]) in Healthy Korean Subjects", 
        "overall_official": {
            "affiliation": "+1 877 822 9493", 
            "last_name": "UCB, Inc.", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2007", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Plasma concentrations of unconjugated Rotigotine", 
                "safety_issue": "No", 
                "time_frame": "Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6"
            }, 
            {
                "measure": "Plasma concentrations of total Rotigotine", 
                "safety_issue": "No", 
                "time_frame": "Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6"
            }, 
            {
                "measure": "Area under the plasma concentration-time curve from 0 to 24 hours at steady-state (AUC (0-24), ss) for unconjugated Rotigotine", 
                "safety_issue": "No", 
                "time_frame": "Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6"
            }, 
            {
                "measure": "Area under the plasma concentration-time curve from 0 to 24 hours at steady-state (AUC (0-24), ss) for total Rotigotine", 
                "safety_issue": "No", 
                "time_frame": "Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6"
            }, 
            {
                "measure": "Area under the plasma concentration-time curve from 0 to 24 hours at steady-state normalized by Body Weight (AUC (0-24), ss, norm (BW)) for unconjugated Rotigotine", 
                "safety_issue": "No", 
                "time_frame": "Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6"
            }, 
            {
                "measure": "Area under the plasma concentration-time curve from 0 to 24 hours at steady-state normalized by Body Weight (AUC (0-24), ss, norm (BW)) for total Rotigotine", 
                "safety_issue": "No", 
                "time_frame": "Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6"
            }, 
            {
                "measure": "Maximum plasma concentration (Cmax) for unconjugated Rotigotine", 
                "safety_issue": "No", 
                "time_frame": "Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6"
            }, 
            {
                "measure": "Maximum plasma concentration (Cmax) for total Rotigotine", 
                "safety_issue": "No", 
                "time_frame": "Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6"
            }, 
            {
                "measure": "Maximum plasma concentration normalized by Body Weight (Cmax, norm (BW)) for unconjugated Rotigotine", 
                "safety_issue": "No", 
                "time_frame": "Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6"
            }, 
            {
                "measure": "Maximum plasma concentration normalized by Body Weight (Cmax, norm (BW)) for total Rotigotine", 
                "safety_issue": "No", 
                "time_frame": "Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01964573"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Area under the plasma concentration-time curve from 0 to 24 hours at steady-state normalized by apparent-dose (AUC (0-24), ss, norm (apparent-dose)) of unconjugated Rotigotine", 
                "safety_issue": "No", 
                "time_frame": "Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6"
            }, 
            {
                "measure": "Area under the plasma concentration-time curve from 0 to 24 hours at steady-state normalized by apparent-dose (AUC (0-24), ss, norm (apparent-dose)) of total Rotigotine", 
                "safety_issue": "No", 
                "time_frame": "Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6"
            }, 
            {
                "measure": "Maximum plasma concentration normalized by apparent-dose (Cmax, norm (apparent-dose)) of unconjugated Rotigotine", 
                "safety_issue": "No", 
                "time_frame": "Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6"
            }, 
            {
                "measure": "Maximum plasma concentration normalized by apparent-dose (Cmax, norm (apparent-dose)) of total Rotigotine", 
                "safety_issue": "No", 
                "time_frame": "Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6"
            }, 
            {
                "measure": "Area under the plasma concentration-time curve from 0 to 24 hours at steady-state normalized by drug content (AUC (0-24), ss, norm (mgdc)) for unconjugated Rotigotine", 
                "safety_issue": "No", 
                "time_frame": "Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6"
            }, 
            {
                "measure": "Area under the plasma concentration-time curve from 0 to 24 hours at steady-state normalized by drug content (AUC (0-24), ss, norm (mgdc)) for total Rotigotine", 
                "safety_issue": "No", 
                "time_frame": "Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6"
            }, 
            {
                "measure": "Maximum plasma concentration normalized by drug content of patch (Cmax, norm (mgdc)) for unconjugated Rotigotine", 
                "safety_issue": "No", 
                "time_frame": "Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6"
            }, 
            {
                "measure": "Maximum plasma concentration normalized by drug content of patch (Cmax, norm (mgdc)) for total Rotigotine", 
                "safety_issue": "No", 
                "time_frame": "Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6"
            }, 
            {
                "measure": "Terminal half-life (t \u00bd) for unconjugated Rotigotine", 
                "safety_issue": "No", 
                "time_frame": "Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6"
            }, 
            {
                "measure": "Terminal half-life (t \u00bd) for total Rotigotine", 
                "safety_issue": "No", 
                "time_frame": "Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6"
            }, 
            {
                "measure": "Time to reach maximum plasma concentration during a dosing interval at steady-state (t max, ss) for unconjugated Rotigotine", 
                "safety_issue": "No", 
                "time_frame": "Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6"
            }, 
            {
                "measure": "Time to reach maximum plasma concentration during a dosing interval at steady-state (t max, ss) for total Rotigotine", 
                "safety_issue": "No", 
                "time_frame": "Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6"
            }, 
            {
                "measure": "Apparent total body clearance (CL/f) for unconjugated Rotigotine", 
                "safety_issue": "No", 
                "time_frame": "Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6"
            }, 
            {
                "measure": "Apparent total body clearance (CL/f) for total Rotigotine", 
                "safety_issue": "No", 
                "time_frame": "Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6"
            }, 
            {
                "measure": "Apparent total body clearance normalized by Body Weight (CL/f norm (BW)) for unconjugated Rotigotine", 
                "safety_issue": "No", 
                "time_frame": "Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6"
            }, 
            {
                "measure": "Apparent total body clearance normalized by Body Weight (CL/f norm (BW)) for total Rotigotine", 
                "safety_issue": "No", 
                "time_frame": "Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6"
            }, 
            {
                "measure": "Apparent total body clearance normalized by apparent-dose (CL/f norm (apparent-dose)) for unconjugated Rotigotine", 
                "safety_issue": "No", 
                "time_frame": "Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6"
            }, 
            {
                "measure": "Apparent total body clearance normalized by apparent-dose (CL/f norm (apparent-dose)) for total Rotigotine", 
                "safety_issue": "No", 
                "time_frame": "Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6"
            }, 
            {
                "measure": "Apparent volume of distribution (Vz/f) for unconjugated Rotigotine", 
                "safety_issue": "No", 
                "time_frame": "Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6"
            }, 
            {
                "measure": "Apparent volume of distribution (Vz/f) for total Rotigotine", 
                "safety_issue": "No", 
                "time_frame": "Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6"
            }, 
            {
                "measure": "Apparent volume of distribution normalized by Body Weight (Vz/f norm (BW)) for unconjugated Rotigotine", 
                "safety_issue": "No", 
                "time_frame": "Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6"
            }, 
            {
                "measure": "Apparent volume of distribution normalized by Body Weight (Vz/f norm (BW)) for total Rotigotine", 
                "safety_issue": "No", 
                "time_frame": "Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6"
            }, 
            {
                "measure": "Plasma concentration at steady-state directly before patch removal (C (24), ss) for total Despropyl Rotigotine", 
                "safety_issue": "No", 
                "time_frame": "Directly before patch removal at Day 2 to Day 7"
            }, 
            {
                "measure": "Plasma concentration at steady-state directly before patch removal (C (24), ss) for total Desthienyl Rotigotine", 
                "safety_issue": "No", 
                "time_frame": "Directly before patch removal at Day 2 to Day 7"
            }, 
            {
                "measure": "Plasma concentration at steady-state 30 hours after last patch application (C (30 h), ss) for total Despropyl Rotigotine", 
                "safety_issue": "No", 
                "time_frame": "At day 7 at 30 hours after last patch application"
            }, 
            {
                "measure": "Plasma concentration at steady-state 30 hours after last patch application (C (30 h), ss) for total Desthienyl Rotigotine", 
                "safety_issue": "No", 
                "time_frame": "At day 7 at 30 hours after last patch application"
            }, 
            {
                "measure": "Amount excreted into urine from 0 to 24 hours at steady-state (Ae (0-24), ss) for unconjungated Rotigotine", 
                "safety_issue": "No", 
                "time_frame": "Day 3 and Day 6 from 0 to after 24 hours of patch application"
            }, 
            {
                "measure": "Amount excreted into urine from 0 to 24 hours at steady-state (Ae (0-24), ss) for total Rotigotine", 
                "safety_issue": "No", 
                "time_frame": "Day 3 and Day 6 from 0 to after 24 hours of patch application"
            }, 
            {
                "measure": "Amount excreted into urine from 0 to 24 hours at steady-state (Ae (0-24), ss) for total Despropyl Rotigotine", 
                "safety_issue": "No", 
                "time_frame": "Day 3 and Day 6 from 0 to after 24 hours of patch application"
            }, 
            {
                "measure": "Amount excreted into urine from 0 to 24 hours at steady-state (Ae (0-24), ss) for total Desthienyl Rotigotine", 
                "safety_issue": "No", 
                "time_frame": "Day 3 and Day 6 from 0 to after 24 hours of patch application"
            }, 
            {
                "measure": "Renal Clearance (CLR) for unconjugated Rotigotine", 
                "safety_issue": "No", 
                "time_frame": "Day 3 and Day 6 from 0 to after 24 hours of patch application"
            }, 
            {
                "measure": "Renal Clearance (CLR) for total Rotigotine", 
                "safety_issue": "No", 
                "time_frame": "Day 3 and Day 6 from 0 to after 24 hours of patch application"
            }
        ], 
        "source": "UCB, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "UCB, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2006", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}